{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:08:54Z","timestamp":1790186934693,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":15,"publisher":"Springer US","isbn-type":[{"value":"9781071632901","type":"print"},{"value":"9781071632918","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3291-8_19","type":"book-chapter","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T08:10:09Z","timestamp":1688631009000},"page":"303-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer"],"prefix":"10.1007","author":[{"given":"Paola","family":"Grandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Darilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anay","family":"Moscu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"24","key":"19_CR1","doi-asserted-by":"publisher","first-page":"13448","DOI":"10.1128\/jvi.77.24.13448-13454.2003","volume":"77","author":"B Salone","year":"2003","unstructured":"Salone B, Martina Y, Piersanti S et al (2003) Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5. J Virol 77(24):13448\u201313454. https:\/\/doi.org\/10.1128\/jvi.77.24.13448-13454.2003","journal-title":"J Virol"},{"issue":"1","key":"19_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh N, Ge Y, Ennist DL et al (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2014armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 12(1):305\u2013313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1059","journal-title":"Clin Cancer Res"},{"issue":"3","key":"19_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/modpathol.3880294","volume":"14","author":"C Cordon-Cardo","year":"2001","unstructured":"Cordon-Cardo C (2001) Applications of molecular diagnostics: solid tumor genetics can determine clinical treatment protocols. Mod Pathol 14(3):254\u2013257. https:\/\/doi.org\/10.1038\/modpathol.3880294","journal-title":"Mod Pathol"},{"issue":"5","key":"19_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/sj.onc.1202385","volume":"18","author":"B Czerniak","year":"1999","unstructured":"Czerniak B, Chaturvedi V, Li L et al (1999) Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18(5):1185\u20131196. https:\/\/doi.org\/10.1038\/sj.onc.1202385","journal-title":"Oncogene"},{"issue":"5","key":"19_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000052494","volume":"39","author":"S Brandau","year":"2001","unstructured":"Brandau S, B\u00f6hle A (2001) Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 39(5):491\u2013497. https:\/\/doi.org\/10.1159\/000052494","journal-title":"Eur Urol"},{"issue":"6","key":"19_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/(sici)1097-0215(19960315)65:6<840::Aid-ijc22>3.0.Co;2-6","volume":"65","author":"Q Wu","year":"1996","unstructured":"Wu Q, Possati L, Montesi M et al (1996) Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16\/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9. Int J Cancer 65(6):840\u2013846. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19960315)65:6<840::Aid-ijc22>3.0.Co;2-6","journal-title":"Int J Cancer"},{"issue":"3","key":"19_CR7","first-page":"493","volume":"55","author":"T Yeager","year":"1995","unstructured":"Yeager T, Stadler W, Belair C et al (1995) Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55(3):493\u2013497","journal-title":"Cancer Res"},{"key":"19_CR8","volume-title":"Fundamental immunology","author":"WE Paul","year":"1993","unstructured":"Paul WE (1993) Fundamental immunology, 3rd edn. Raven Press, New York","edition":"3"},{"issue":"1","key":"19_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11481-010-9226-7","volume":"6","author":"RA Rifkin","year":"2011","unstructured":"Rifkin RA, Maggio ET, Dike S et al (2011) N-dodecyl-\u03b2-D-maltoside inhibits aggregation of human interferon-\u03b2-1b and reduces its immunogenicity. J Neuroimmune Pharmacol 6(1):158\u2013162. https:\/\/doi.org\/10.1007\/s11481-010-9226-7","journal-title":"J Neuroimmune Pharmacol"},{"issue":"7","key":"19_CR10","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1212\/wnl.54.7.1414","volume":"54","author":"DE Goodkin","year":"2000","unstructured":"Goodkin DE, Shulman M, Winkelhake J et al (2000) A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. Neurology 54(7):1414\u20131420. https:\/\/doi.org\/10.1212\/wnl.54.7.1414","journal-title":"Neurology"},{"issue":"3","key":"19_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0169-409X(98)00012-X","volume":"32","author":"RK Gupta","year":"1998","unstructured":"Gupta RK, Singh M, O\u2019Hagan DT (1998) Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 32(3):225\u2013246","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"19_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke JM, Lamm DL, Meng MV et al (2012) A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 188(6):2391\u20132397. https:\/\/doi.org\/10.1016\/j.juro.2012.07.097","journal-title":"J Urol"},{"issue":"10","key":"19_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA et al (2018) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 36(10):440\u2013447. https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005","journal-title":"Urol Oncol"},{"issue":"16_suppl","key":"19_CR14","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1200\/JCO.2022.40.16_suppl.4574","volume":"40","author":"R Li","year":"2022","unstructured":"Li R, Spiess PE, Sexton WJ et al (2022) Preliminary results from phase Ib\/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC). J Clin Oncol 40(16_suppl):4574. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4574","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"19_CR15","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","volume":"40","author":"R Li","year":"2022","unstructured":"Li R, Steinberg GD, Uchio EM et al (2022) CORE1: phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). J Clin Oncol 40(16_suppl):4597. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4597","journal-title":"J Clin Oncol"}],"container-title":["Methods in Molecular Biology","Urothelial Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3291-8_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T08:11:50Z","timestamp":1688631110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3291-8_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071632901","9781071632918"],"references-count":15,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3291-8_19","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"7 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}